Personensuche
Personensuche
Es wurde 1 Person gefunden.
Anschrift
Universitätsstr. 5
45141 Essen
45141 Essen
Raum
S05 T04 B23
Telefon
E-Mail
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
Keine vergangenen Veranstaltungen.
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Anthracycline Therapy Modifies Immune Checkpoint Signaling in the HeartIn: International Journal of Molecular Sciences (IJMS) , Jg. 24 2023, Nr. 7, 6052DOI, Online Volltext (Open Access)
-
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapyIn: European Heart Journal , Jg. 43 2022, Nr. 4, S. 316 – 329
-
Superiority of focused ion beam-scanning electron microscope tomography of cardiomyocytes over standard 2D analyses highlighted by unmasking mitochondrial heterogeneityIn: Journal of Cachexia, Sarcopenia and Muscle , Jg. 12 2021, Nr. 4, S. 933 – 954DOI, Online Volltext (Open Access)
-
Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastomaIn: Cancer Letters , Jg. 455 2019, S. 24 – 33
-
RITA displays anti-tumor activity in medulloblastomas independent of TP53 statusIn: OncoTarget , Jg. 8 2017, Nr. 17, S. 27882 – 27891DOI (Open Access)
-
Targeting tachykinin receptors in neuroblastomaIn: OncoTarget , Jg. 8 2017, Nr. 1, S. 430 – 443DOI (Open Access)
-
The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma modelsIn: OncoTarget , Jg. 8 2017, Nr. 4, S. 6730 – 6741DOI (Open Access)
-
Targeting MYCN-driven transcription by BET-bromodomain inhibitionIn: Clinical Cancer Research , Jg. 22 2016, Nr. 10, S. 2470 – 2781DOI (Open Access)
-
Absence of telomerase reverse transcriptase promoter mutations in neuroblastomaIn: Biomedical Reports , Jg. 3 2015, Nr. 4, S. 443 – 446
-
Mutational dynamics between primary and relapse neuroblastomasIn: Nature Genetics , Jg. 47 2015, Nr. 8, S. 872 – 877
-
Targeting super-enhancer induced gene expression with the novel BRD4 inhibitor OTX015 in preclinical models of MYCN-amplified neuroblastomaIn: Cancer Research , Jg. 75 2015, Nr. 15 Suppl., S. 4731
-
miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating SurvivinIn: International Journal of Cancer , Jg. 136 2015, Nr. 6, S. 1308 – 1320DOI (Open Access)
-
BET protein inhibitor OTX015 has selective anti-tumoral activity in preclinical models of MYCN- amplified neuroblastomaIn: Cancer Research , Jg. 74 2014, Nr. 19 Suppl., S. 3967
-
Neuroblastoma in dialog with its stroma : NTRK1 is a regulator of cellular cross-talk with Schwann cellsIn: OncoTarget , Jg. 5 2014, Nr. 22, S. 11180 – 11192DOI (Open Access)
-
BET bromodomain protein inhibition is a therapeutic option for medulloblastomaIn: OncoTarget , Jg. 4 2013, Nr. 11, S. 2080 – 2095
-
MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1AIn: International Journal of Cancer , Jg. 133 2013, Nr. 5, S. 1064 – 1073
-
Targeted expression of mutated ALK induces neuroblastoma in transgenic miceIn: Science Translational Medicine , Jg. 4 2012, Nr. 141, S. 141ra91
-
Pharmacologic activation of the p53 pathway using Nutlin-3 inhibits medulloblastoma cell proliferation in vitroIn: Klinische Pädiatrie , Jg. 221 2009, Nr. 3, S. 201
-
The mutagenic potential of non-homologous end joining in the absence of the NHEJ core factors Ku70/80, DNA-PKcs and XRCC4-LigIVIn: Mutagenesis , Jg. 22 2007, Nr. 3, S. 217 – 233
-
Analysis of double-strand break repair by nonhomologous DNA end joining in cell-free extracts from mammalian cellsIn: Molecular Toxicology Protocols / Keohavong, Phouthone; Grant, Stephen G. (Hrsg.) 2014, S. 565 – 585